BAY 2416964 |
| رقم الكتالوجGC60622 |
BAY 2416964 هو مضاد لمستقبلات أريل هيدروكربون قوية وفعالة عن طريق الفم مستخرج من براءة اختراع WO2018146010A1 ، المثال 192 ، يحتوي على IC50 من 341 نانومتريتمتع BAY 2416964 بإمكانية علاج الأورام الصلبة
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2242464-44-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BAY 2416964 is a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018146010A1, example 192, has an IC50 of 341 nM. BAY 2416964 has the potential for solid tumors treatment[1].
BAY 2416964 (Example 192) induces AHR-regulated gene CYP1A1 expression in a human monocytic U937 cells with an IC50 of 4.3 nM[1].
[1]. Ilona GUTCHER, et al. 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer. WO2018146010A1
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *